Atara Biotherapeutics, Inc. (ATRA)
NASDAQ: ATRA · Real-Time Price · USD
8.77
+0.22 (2.57%)
Aug 4, 2026, 4:00 PM EDT - Market closed
Atara Biotherapeutics Balance Sheet
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Assets
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Cash & Equivalents | 8.36 | 8.48 | 25.03 | 25.84 | 92.94 | 106.08 |
Short-Term Investments | - | - | 17.47 | 25.88 | 149.88 | 264.98 |
Cash & Short-Term Investments | 8.36 | 8.48 | 42.5 | 51.73 | 242.82 | 371.07 |
Cash Growth | -39.60% | -80.04% | -17.84% | -78.70% | -34.56% | -25.88% |
Accounts Receivable | - | 1.25 | 1.48 | 34.11 | 40.22 | 0.99 |
Inventory | - | - | 10.66 | 9.71 | 1.59 | - |
Other Current Assets | 3.81 | 2.48 | 10.26 | 6.33 | 10.45 | 12.57 |
Total Current Assets | 12.17 | 12.21 | 64.89 | 101.87 | 295.08 | 384.62 |
Net Property, Plant & Equipment | 6.93 | 7.14 | 41.1 | 58.79 | 74.32 | 79.94 |
Other Long-Term Assets | 0.89 | 0.89 | 3.1 | 4.84 | 7.02 | 3.57 |
Total Assets | 20 | 20.24 | 109.1 | 165.5 | 376.42 | 468.13 |
Liabilities
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Accounts Payable | 0.64 | 0.13 | 4.37 | 3.68 | 6.87 | 17.37 |
Accrued Expenses | 0.67 | 1.35 | 14.57 | 28.88 | 42.65 | 38.6 |
Unearned Revenue | 0.68 | 0.72 | 95.09 | 77.83 | 8 | 40.76 |
Other Current Liabilities | 3.65 | 12.73 | 20.54 | 31.83 | 21.39 | 9.06 |
Total Current Liabilities | 5.65 | 14.92 | 134.57 | 142.23 | 78.92 | 105.79 |
Long-Term Leases | 9.08 | 9.35 | 29.91 | 45.69 | 58.06 | 25.52 |
Other Long-Term Liabilities | 42.59 | 34.47 | 41.89 | 76.82 | 112.8 | 57.21 |
Total Long-Term Liabilities | 51.66 | 43.82 | 71.81 | 122.51 | 170.86 | 82.73 |
Total Liabilities | 57.31 | 58.74 | 206.38 | 264.74 | 249.78 | 188.51 |
Shareholders' Equity
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Common Stock | 0 | 0 | 0 | - | 0.01 | 0.01 |
Additional Paid-in Capital | 1,989 | 1,983 | 1,957 | 1,870 | 1,822 | 1,745 |
Accumulated Other Comprehensive Income | - | 0 | 0.01 | -0.2 | -2.07 | -0.37 |
Retained Earnings | -2,026 | -2,022 | -2,055 | -1,969 | -1,693 | -1,465 |
Shareholders' Equity | -37.31 | -38.5 | -97.28 | -99.23 | 126.64 | 279.61 |
Total Liabilities & Equity | 20 | 20.24 | 109.1 | 165.5 | 376.42 | 468.13 |
Additional Metrics
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Total Debt | 9.08 | 9.35 | 29.91 | 45.69 | 58.06 | 25.52 |
Net Cash (Debt) | -0.72 | -0.87 | 12.58 | 6.03 | 184.76 | 345.55 |
Net Cash Growth | - | - | 108.59% | -96.73% | -46.53% | -29.13% |
Net Cash Per Share | -0.05 | -0.07 | 1.68 | 1.42 | 45.29 | 92.22 |
Book Value | -37.31 | -38.5 | -97.28 | -99.23 | 126.64 | 279.61 |
Book Value Per Share | -2.75 | -3.03 | -12.99 | -23.43 | 31.04 | 74.63 |
Tangible Book Value | -37.31 | -38.5 | -97.28 | -99.23 | 126.64 | 279.61 |
Tangible Book Value Per Share | -2.75 | -3.03 | -12.99 | -23.43 | 31.04 | 74.63 |